KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: The activation of NKG2D induces the reactivity of NK cells against tumor cells [56], but the expression of this marker is negatively modulated in patients with CML and other types of cancer, which facilitates the escape of tumor cells [57].